Whalesbook
CMS Announces Payment Boost
Major US health insurers saw substantial stock gains on Monday, April 6. UnitedHealth Group (UNH) climbed as much as 10%, Humana (HUM) surged by 13%, and CVS Health (CVS) rose 8%. This surge followed the Centers for Medicare and Medicaid Services (CMS) final decision to increase Medicare Advantage (MA) payment rates for 2027 by 2.48%.
This is a significant increase from the initial January proposal of just 0.09%. The earlier, lower proposal had triggered a sharp sell-off, erasing an estimated $100 billion in market value for the sector. The revised policy, which guides over half a trillion dollars in federal funding, is now expected to add about $13 billion to Medicare Advantage plans next year.
Analysts had previously seen an increase between 1% and 1.5% as sufficient, making Monday's announcement a positive surprise.
Industry Reaction and Financials
The sharp market swing shows the health insurance industry's strong lobbying efforts and its heavy reliance on government payment rates. UnitedHealth Group, with a market cap of approximately $255.45 billion and a P/E ratio around 20.95, shows a P/E near its 12-month average. Humana, boasting a market cap of roughly $21.45 billion, trades at a P/E of approximately 18.13. CVS Health, with a market cap of about $93.49 billion, currently exhibits a P/E ratio around 52.87, significantly higher than its historical average and peer group, suggesting a potentially unusual market valuation.
Before this announcement, the sector faced significant challenges. Rising medical costs and the potential expiration of enhanced ACA subsidies were creating a tough environment, with some expecting shrinking profit margins for insurers. The initial Medicare rate proposal intensified these worries, leading to a reevaluation of industry valuations.
Raymond James analyst Chris Meekins called the final rate "better than expected," suggesting it could support two years of earnings growth. CMS officials, however, stressed their focus on balancing program stability and financial health. They also signaled ongoing scrutiny of insurer practices that boost profits, like upcoding and other risk adjustment tactics.
Lingering Risks Remain
Despite the immediate relief, significant risks remain for health insurers dealing with the complex regulatory environment. Humana, for example, is involved in litigation challenging its 2025 Medicare Advantage Star Ratings. An unfavorable outcome could hurt its 2026 quality bonus payments and financial results.
The company's revenue heavily relies on government contracts like Medicare and Medicaid, exposing it to risks from contract losses, audits, and insufficient payment rates. Cybersecurity threats also pose a constant concern, with risks of data breaches, regulatory fines, and reputational damage.
Insurers generally face ongoing pressure from rising medical costs, which are expected to continue impacting profits. For instance, the individual health insurance market anticipates significant premium hikes in 2026 due to rising medical costs and the expiration of enhanced premium tax credits.
While the Medicare Advantage rate hike eases immediate funding worries for 2027, CMS's stated commitment to accountability and potentially curbing insurer profits through scrutiny of coding practices indicates an ongoing regulatory balancing act. The industry's challenge of controlling rising medical costs within government payment limits persists.
Analyst Views
Analysts generally view the increased MA rates positively for near-term earnings. Raymond James upgraded UnitedHealth Group to 'outperform' with a $330 price target, citing potential upside.
Humana has a consensus 'Hold' rating from 29 firms, with its average one-year price target suggesting over 18% upside. The sector's ability to manage rising costs and adapt to evolving regulatory needs, especially regarding quality metrics and risk adjustment, will be crucial for sustained long-term performance.
The market's immediate reaction is relief, but CMS's ongoing scrutiny of insurer profits and cost control suggests insurers and regulators will continue to negotiate.